ArticlePigment cell & melanoma research2011
Clinical relevance of SKP2 alterations in metastatic melanoma.
Article in Pigment cell & melanoma research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- E3 ubiquitin ligase SKP2 limits autophagosome formation duringFrontiers in cellular and infection microbiology · 2026Article
- A pan-cancer analysis revealedPrecision clinical medicine · 2025Article
- Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway.Genes & diseases · 2023Article
- SKP2 Contributes to AKT Activation by Ubiquitination Degradation of PHLPP1, Impedes Autophagy, and Facilitates the Survival of Thyroid Carcinoma.Molecules and cells · 2023Article
- Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.British journal of cancer · 2022Review
- Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality.Cell death & disease · 2022Article
- CircRNA-Associated CeRNAs Regulatory Axes in Retinoblastoma: A Systematic Scoping Review.Frontiers in oncology · 2022Article
- The NUCKS1-SKP2-p21/p27 axis controls S phase entry.Nature communications · 2021Article
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.Nature communications · 2019Article
- SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination.Journal of experimental & clinical cancer research : CR · 2019Article
- Prognostic values of F-box members in breast cancer: an online database analysis and literature review.Bioscience reports · 2019Review
- Article
- SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27.OncoTargets and therapy · 2019Article
- Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.Oncology letters · 2018Article
- F-box proteins involved in cancer-associated drug resistance.Oncology letters · 2018Review
- S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.Cell cycle (Georgetown, Tex.) · 2017Article
- microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- MicroRNA regulation of F-box proteins and its role in cancer.Seminars in cancer biology · 2016Review
- Expression of Skp2 and p27Oncology letters · 2015Article
- Dysregulation of ubiquitin ligases in cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
In this study, we investigated the mechanism(s) of altered expression of protooncogene SKP2 in metastatic melanoma and its clinical relevance in patients with metastatic melanoma. The genomic status of SKP2 was assessed in cell lines by sequencing, single nucleotide polymorphism array, and genomic PCR. Copy number status was then evaluated for concordance with SKP2 mRNA and protein expression. SKP2 protein was further evaluated by immunohistochemistry in 93 human metastatic tissues. No mutations were identified in SKP2. Increased copy number at the SKP2 locus was observed in 6/14 (43%) metastatic cell lines and in 9/22 (41%) human metastatic tissues which was associated with overexpression of SKP2 protein. Overexpression of SKP2 protein in human tissues was associated with worse survival in a multivariate model controlling for the site of metastasis. Copy number gain is a major contributing mechanism of SKP2 overexpression in metastatic melanoma. Results may have implications for the development of therapeutics that target SKP2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.